Adjuvance on forefront of COVID-19 vaccine battle

By Macy Meyer at

Adjuvance is developing a component that will strengthen a vaccine and prolong its dosage.

Tucked away in one of the many labs on Nebraska’s Innovation Campus lays the company Adjuvance. At the beginning of the year they were asked by the National Institute of Health to join in on the global race to fight COVID–19. Four months later they’re making strides.

“We have plans right now to make a million doses of our adjuvant by the end of the year and 100 million doses by next fall,” CEO Dr. Tyler Martin said.